¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29
±³À°ÀÏÀÚ : 2022-04-29
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ
´ã´çÀÚ : ¹Ú¼Ò¹Î
¿¬¶ôó : 02-398-5055  
À̸ÞÀÏ : office@kscpt.org      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¸¶ÃëÅëÁõÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã 
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í ¿Â¶óÀÎ Âü¼® : Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 2¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 10¸¸¿ø, ºñȸ¿ø Çлý 5¸¸¿ø  ÇöÀåÂü¼® : Á¤È¸¿ø 7¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 12¸¸¿ø, ºñȸ¿ø Çлý 8¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:00~13:40 Special lecture : Facts and Misconceptions about Aducanumab Approval  Yaning Wang(Createrna Science and Technology) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:40~14:10 Model guided dose escalation in oncology Phase 1 trial  ±èÀ翬(Novartis Institutes for Biomedical Research (Cambridge MA USA)) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:10~14:40 Exposure-response relationship for current and future drug development  ¿ÀÀ缺(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:40~15:10 Recent advances in exposure-response relationship in drug development  ±èÁ¾·ü(ÀÎÁ¦´ë ºÎ»ê¹éº´¿ø) 
Åä·Ð 04-29 ¿Â¶óÀΠ15:10~15:30 Åä·Ð  () 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ15:30~16:00 Exposure-Response in Cancer: Starting from Genomics  ±è±ÔÇ¥(¿ï»ê´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:00~16:30 Experiences to Characterize Exposure-Response Relationship for Various Therapeutics using Modeling and Simulation: Advantages and Challenges  ÇѼºÇÊ(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:30~17:00 Exposure-Response RelationshipÀ» ÀÌ¿ëÇÑ ½Å¾à°³¹ß °æÇè  ÀÌÁöÀº(LG »ý¸í°úÇÐ) 
Åä·Ð 04-29 ¿Â¶óÀΠ17:00~17:20 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ½ÉÀå´ë»çÁõÈıºÇÐȸ 2022 5th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS(1ÀÏÂ÷) : 2022-04-29
´ÙÀ½±Û (¿Â¶óÀÎ) ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­¿ï µ¿ºÎÁöȸ ¿ù·ÊÁý´ãȸ : 2022-04-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20589 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GI Cancer 2024 : 2024-06-14 0 50 2024-04-29
20588 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-06-14 0 47 2024-04-29
20587 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 2ÀÏÂ÷ : 2024-06-14 0 35 2024-04-29
20586 °æºÏ 2024 ´ëÇÑÆó¾ÏÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-14 0 45 2024-04-29
20585 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 1ÀÏÂ÷ : 2024-06-13 0 47 2024-04-29
20584 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-13 0 49 2024-04-29
20583 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-ÃÖ½ÅÇü º¸Ã»±â¿Í ¸ÂÃãÇü º¸Ã»±â ó¹æ¿ä·É : 2024-06-13 0 36 2024-04-29
20582 ¼­¿ï °­³²¼¼ºê¶õ½º ¾È°ú Áö¿ªÀÇ»çÁý´ãȸ(³­Ä¡¼º °¢¸· Áúȯ) : 2024-06-11 0 56 2024-04-29
20581 ¼­¿ï [¿Â¶óÀÎ] Á¦274ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ(Æó±â´É°ú ±â°üÁö°ú¹Î¼º) : 2024-06-11 0 35 2024-04-29
20580 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø [¿Â¶óÀÎ] Á¦ 26 ȸ ¿Ü·¡Â÷¿øÀÇ ¼Ò¾Æû¼Ò³â°ú ÀÓ»ó : 2024-06-09 0 37 2024-04-29
20579 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø ¼øȯ±â³»°ú 16ȸ KOALA Symposium 2024 : 2024-06-09 0 37 2024-04-29
20578 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ (¿Â¶óÀÎ) Á¦3ȸ ¼ö¸é°øµ¿½ÉÆ÷Áö¾ö : 2024-06-09 0 52 2024-04-29
20577 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ 2024 ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-09 0 60 2024-04-29
20576 ¼­¿ï 2024 ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-08 0 55 2024-04-29
20575 ¼­¿ï 2024 »ó¹Ý±â ´ëÇÑÇ÷¾×ÇÐȸ ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ ½ÉÆ÷Áö¾ö(2024 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸¸ðÀÓ) : 2024-06-08 0 37 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷